Bezlotoxumab Injection
Bezlotoxumab injection (Zinplava) is a targeted antibody therapy used to help prevent Clostridioides difficile (C. diff) infection from coming back in adults and children 1 year and older who are already being treated with antibiotics.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 1 clinical label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
📖 Bezlotoxumab Injection: Patient Information Guide
A plain-language walkthrough of Bezlotoxumab Injection — what it treats, how it works, how it’s taken, side effects, warnings and interactions. Tap any section to expand it.
🎯What it's used for▾
Bezlotoxumab injection (brand: Zinplava) is approved for one specific purpose: reducing the chance that a Clostridioides difficile (C. diff) gut infection will return.
- Zinplava is used to reduce recurrence of Clostridioides difficile infection (CDI) in adults and in children 1 year of age and older who are currently receiving antibiotic treatment for CDI and are considered at high risk for the infection coming back.
- Zinplava must always be used together with antibiotic treatment — it is not a standalone treatment for C. diff and is not itself an antibiotic.
- Zinplava is not approved for children younger than 1 year of age.
⚙️How it works▾
Zinplava (bezlotoxumab) is a human monoclonal antibody — a precisely engineered protein that targets a specific substance in the body. It works by binding directly to C. difficile toxin B, one of the harmful toxins the bacteria release that damages the gut lining and drives infection. By latching onto toxin B and neutralizing it, Zinplava helps block the toxin's damaging effects and reduce the likelihood of C. diff coming back.
Because Zinplava targets toxin B directly rather than going through the liver's enzyme systems, no metabolic drug interactions are expected with other medications.
💊How it's taken▾
Zinplava is given as a single intravenous (IV) infusion — a drip into a vein — over 60 minutes. It is dosed based on body weight and given just once during a course of antibiotic treatment for C. diff. You do not take it at home; a healthcare provider prepares and administers it in a clinical setting.
- It must be diluted before infusion — it is never given as a direct push or bolus injection.
- No other drugs should run through the same IV line at the same time.
- The safety of giving it more than once has not been studied.
🤒Side effects — in detail▾
Most people tolerate Zinplava well. The most common side effects seen in clinical trials include:
- Nausea
- Fever (pyrexia)
- Headache
- Fatigue (on the day of or day after infusion)
- Dizziness
- Shortness of breath (dyspnea)
- High blood pressure during infusion
Infusion-related reactions are generally mild to moderate and typically resolve within 24 hours. However, serious heart failure events were reported — particularly in patients who already had congestive heart failure — so tell your care team immediately if you notice worsening breathing, swelling, or other new heart-related symptoms after your infusion.
⚠️Warnings & precautions▾
- Heart failure risk: In clinical trials, patients with a history of congestive heart failure (CHF) who received Zinplava had a meaningfully higher rate of serious heart failure events and deaths compared to those who did not receive it. If you have CHF, your doctor must carefully weigh the benefits against this risk before giving Zinplava.
- Infusion-related reactions: About 10% of patients experienced a reaction on the day of or day after infusion — including nausea, headache, fever, dizziness, or shortness of breath. These are usually mild and short-lived.
- Heart rhythm: One patient in trials developed a serious irregular heartbeat (ventricular tachyarrhythmia) during infusion, requiring the infusion to be stopped. You will be monitored during administration.
- Not a C. diff treatment on its own: Zinplava does not treat the active infection — always use it alongside the prescribed antibiotic.
🔀What it interacts with▾
Zinplava is broken down by the body's natural protein-recycling process (catabolism) rather than through liver enzymes, so drug-drug interactions involving metabolism are not expected. No specific drug interactions are identified in the prescribing information.
- No other medications should be infused through the same IV line at the same time as Zinplava — keep lines separate during administration.
This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.
📋Before taking it▾
- History of congestive heart failure (CHF): Tell your doctor — Zinplava is associated with higher rates of serious heart failure events in people with this condition and should only be used if the benefit clearly outweighs the risk.
- Pregnancy: There are no adequate studies in pregnant women. Discuss the risks and benefits with your doctor.
- Breastfeeding: It is unknown whether Zinplava passes into breast milk. Talk to your doctor about the best approach for you and your baby.
- Children under 1 year: Safety and effectiveness have not been established in this age group — Zinplava is not approved for infants under 1 year old.
- Older adults (65+): No dose adjustment is needed. Safety and effectiveness were similar to younger adults in clinical trials.
🚑If you take too much▾
There is no clinical experience with Zinplava overdose. If too much is given, the patient should be closely monitored for any signs or symptoms of side effects, and supportive care should be provided as needed. Contact a healthcare provider or poison control center immediately if an overdose is suspected.
🔬Pharmacokinetics — how your body processes it▾
After a single weight-based IV infusion, Zinplava reaches its peak level in the bloodstream during the infusion itself. It stays in the body for an extended period — its elimination half-life (the time it takes for half the drug to leave the body) is approximately 19 days.
The body clears Zinplava through catabolism — the same natural process used to break down other proteins — rather than through liver enzymes. People who weigh more clear the drug a little faster, but the weight-based dosing approach accounts for this. Factors like gender, race, ethnicity, and other medical conditions do not meaningfully change how the body handles Zinplava.
📦How to store it▾
Store in a refrigerator, 2ºC to 8ºC (36ºF to 46ºF) in original carton to protect from light. Do Not Freeze.
📄 Written from Bezlotoxumab Injection’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Every point is grounded in that labeling — nothing is invented. How we use AI →
🩺 Pharmacist Counseling Corner
Quick, plain-English answers to the questions patients ask most about Bezlotoxumab Injection — the kind of thing our pharmacy team would talk through with you at the counter.
What exactly is Zinplava doing — is it an antibiotic that kills the C. diff bacteria? ▾
I'm already taking an antibiotic for C. diff. Why do I need Zinplava on top of that? ▾
Will I need to come in for multiple infusions, or is this a one-time thing? ▾
What side effects should I expect, and when should I call someone? ▾
I have congestive heart failure. Is Zinplava safe for me? ▾
I'm pregnant or breastfeeding — is Zinplava okay to use? ▾
Is Bezlotoxumab Injection available over the counter? ▾
When was Bezlotoxumab Injection first available? ▾
Who makes Bezlotoxumab Injection? ▾
💬 Answers drafted from Bezlotoxumab Injection’s FDA-approved label information, summarized in plain language with AI, and reviewed by our pharmacy team before publication. Grounded in that labeling — nothing is made up. How we use AI →
🧰 Keep exploring
💊 How Bezlotoxumab Injection comes
Bezlotoxumab Injection is available in 1 form. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Injection
How this form is used
- Zinplava is used to reduce the recurrence of Clostridioides difficile infection (CDI) in adults and pediatric patients 1 year of age and older who are receiving antibiotic treatment for CDI and are at high risk for CDI coming back
- Zinplava must be diluted before administration and is given as a single intravenous infusion over 60 minutes
- Zinplava is administered during — not instead of — antibiotic treatment for C. diff
- Zinplava must not be given as an intravenous push or bolus, and no other drugs should be infused through the same line at the same time
- Zinplava is dosed based on body weight and is given only once; repeat administration has not been studied
📊 Bezlotoxumab Injection across the U.S. market
How Bezlotoxumab Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
🔍 Compare Bezlotoxumab Injection products
A representative set of FDA-listed product records for Bezlotoxumab Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 25 mg/mL | Intravenous | Merck Sharp & Dohme LLC × 3 listings | BLA | View NDC → |
| 25 mg/mL | — | MSD Ireland (Carlow) | DRUG FOR FURTHER PROCESSING | View NDC → |
Showing 4 of 4 products — FDA National Drug Code Directory. See every product, package size and price: browse all 4 Bezlotoxumab Injection NDCs →
📈 What people report — real-world data (FDA FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Bezlotoxumab Injection — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Bezlotoxumab Injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
🏛️ The road to your pharmacy
How Bezlotoxumab Injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
🚨 Recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
Source: openFDA drug enforcement (recall) reports.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 1855048 1 dose form · 1 strength
-
Dose form (SCDF) Injection RxCUI 1855051In current FDA listingsClinical drug / strength (SCD) 40 ML bezlotoxumab 25 MG/MLRxCUI 1855052
Look up RxCUI 1855048 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
📦 Supply & shortage status
Whether Bezlotoxumab Injection is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
🏷️ Sold under these brand names
🏭 Manufacturers & labelers
RxNorm drug class
Bezlotoxumab Injection belongs to the Antibacterial monoclonal antibodies class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
🔬 Where this comes from
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How we combine label and product data
HelloPharmacist combines public FDA and NLM records; we don’t author the underlying clinical facts. We identified 1 FDA-filed SPL label set within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. The representative label is the starting point for the displayed reference monograph; the 12 largest stored in-scope SPL records, which may include that representative, are compared section by section, and the longest available version of each section is retained. Forms, routes, brands, labelers, product-listed strengths, and product-record counts are aggregated separately from ingredient-matched FDA NDC Directory records; package records listed above are associated with the linked SPL; and the normalized concept hierarchy comes from NLM RxNorm.
Where a section is identified as AI-written, its plain-language text is generated from bounded label evidence. New draft drug pages remain in the admin review queue before first publication. Merck Sharp & Dohme LLC is the representative DailyMed label linked for verification and dates; it is not the sole source used for the page.
This is general education, not medical advice — always consult your doctor or pharmacist about your medications and any medical condition. For the exact wording of the linked representative label, view that label on DailyMed; some displayed composite sections may come from other in-scope SPL labels. Learn how we use AI and our data sources & update cadence.